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1  Summary 
 
Visceral obesity is an independent risk factor for the development of cardiovascular diseases 
and type 2 diabetes. This is likely due to inherent difference compared to subcutaneous fat 
(e.g. in cellular composition, adipokine release, etc.) and/or due to different venous drainage 
since secreted products such as adipocytokines and FFAs from subcutaneous fat are drained 
systemically into the vena cava, whereas secreted product from mesenteric or visceral fat are 
drained into the portal system. Exaggerated hepatic delivery of FFAs and pro-inflammatory 
cytokines originating from adipose tissue (and/or the gastrointestinal tract) result in hepatic 
insulin resistance and metabolic deterioration constituting "the portal theory". 
The aim of this study was to determine the effects of excessive adipose tissue on whole-body 
glucose homeostasis depending on venous drainage of adipose tissue. 
To obtain an artificial increase in adipose tissue mass, fat tissue transplantation was 
performed in mice. Epididymal fat pads of a donor mouse were stitched to the mesenterium of 
an acceptor mouse, thus, draining into portal vein simulating visceral fat accumulation. 
Alternatively, epididymal fat pads were stitched to the peritoneum of an acceptor mouse. In 
the latter model, fat transplants are drained systemically via vena cava. As controls, sham-
operated littermates were analyzed. 
Four weeks after transplantation glucose tolerance was determined by an intraperitoneal 
glucose tolerance test. Mice receiving systemic drained fat pads showed an improved glucose 
tolerance compared to sham-operated controls. In contrast, mice with portal transplanted fat 
pads showed an impaired glucose tolerance. Moreover, hepatic insulin resistance developed in 
portal-transplanted mice as assessed by a hyperinsulinemic-euglycemic clamp. In addition, 
insulin-stimulated Akt-phosphorylation was reduced in liver samples of portal-transplanted 
mice suggesting reduced hepatic insulin signalling. mRNA expression of Interleukin-6 (IL-6) 
was upregulated in portal-transplanted adipose tissue compared to the systemic-drained 
transplant. Furthermore, IL-6 concentration was increased in portal but not in systemic plasma 
samples of mice receiving a portal fat transplant. Intriguingly, wildtype mice receiving a 
portal fat transplant from IL-6 knockout mice showed normal glucose tolerance. 
In conclusion, our results demonstrate that the metabolic fate of intra-abdominal fat tissue 
transplantation is determined by the delivery of inflammatory cytokines to the liver 
specifically via the portal system providing clear direct support for the portal hypothesis. 
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2  Zusammenfassung 
 
Viszerale Adipositas ist ein unabhängiger Risikofaktor für die Entstehung kardiovaskulärer 
Erkrankungen und des Typ 2 Diabetes. Dieser Zusammenhang beruht wahrscheinlich 
einerseits auf intrinsischen Unterschieden zwischen viszeralem und subkutanem Fettgewebe 
(zelluläre Zusammensetzung, Produktion von Zytokinen und Adipokinen), andererseits auf 
einer unterschiedlichen venösen Drainage dieser Fettgewebe. Viszerales Fettgewebe wird von 
der Pfortader drainiert. Entsprechend wird bei einer vermehrten Freisetzung von Zytokinen 
und Fettsäuren aus dem viszeralen Fettgewebe (beispielsweise im Rahmen einer Adipositas) 
die Leber solchen Veränderung direkt ausgesetzt und es kann sich eine hepatische 
Insulinresistenz entwickeln.   
Ziel dieser Arbeit war es, mittels Fetttransplantation an Mäusen die Auswirkungen von 
Fettgewebslokalisation und entsprechend venöser Drainage der Fettgewebe auf die 
Glukosehomöostase zu untersuchen.  
Epididymales Fettgewebe wurde einer Donor-Maus entnommen und anschliessend entweder 
ans Mesenterium oder ans Peritoneum einer Akzeptor-Maus genäht. Im ersten Fall wird das 
Transplantat portal drainiert, im zweiten Fall caval/systemisch. Dadurch wurde einerseits eine 
Zunahme des viszeralen und daher portal drainierten Körperfettes und andererseits eine 
Zunahme des subkutanen und daher systemisch drainierten Körperfettes simuliert. Alle 
Transplantate waren nach fünf Wochen gut durchblutet und morphologisch unauffällig. Als 
Kontrolle dienten Mäuse, die zwar operiert wurden aber kein Transplantat erhielten (Sham). 
Vier Wochen nach Transplantation zeigten Mäuse, die ein systemisch drainiertes 
Fetttransplantat erhielten, eine im Vergleich zu Sham-operierten Mäuse eine verbesserte 
Glukosetoleranz, während Mäuse mit einem portal drainierten Transplantat eine 
verschlechterte Toleranz aufwiesen. Zudem ergab eine hyperinsulinämische-euglykämische 
Clamp eine hepatische Insulinresistenz in portal transplantierten Mäusen. Auch fand sich eine 
verminderte insulin-induzierte Phosphorylierung von Akt in der Leber portal transplantierter 
Mäuse, vereinbar mit vermindertem hepatischen Insulinsignalling. mRNA Expression von 
Interleukin-6 (IL-6) war erhöht in portal transplantiertem verglichen mit systemisch 
transplantiertem Fettgewebe. Auch fand sich eine erhöhte IL-6 Konzentration in portalem 
aber nicht im sytemischem Plasma von portal transplantierten Mäusen.  Insbesondere zeigten 
Wildtyp-Mäuse, welche ein portales Fett-Transplantat von IL-6 Knockoutmäusen erhielten, 
eine normale Glukosetoleranz auf.  
 5
Schlussfolgernd lässt sich sagen, dass die Lokalisation und Drainage von Fettgewebe den 
Glukosestoffwechsel beeinflusst, wobei vor allem die portale Drainage von viszeralem 
Fettgewebe an der Entstehung einer hepatischen Insulinresistenz entscheidend beteiligt zu 
sein scheint.  
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3  Abbreviations 
 
ACS               Acyl-CoA Synthetase 
ACOD           Acyl-CoA-Oxidase 
Akt                 v-akt murine thymoma viral oncogene (PKB) 
ANOVA        Analysis of variance 
cDNA            complementary Deoxyribonucleic acid 
DAB              3,3′-diaminobenzidine tetrahydrochloride 
dNTP           Deoxyribonucleotide triphosphate 
DTT              Dithiotreitol 
EGTA           Ethylene glycol tetraacetic acid 
ELISA          Enzyme Linked Immunosorbent Assay 
FFA           Free fatty acid 
HE           Haematoxilin Eosin 
IL-6               Interleukin 6 
MEHA          3-methyl-N-Ethyl-N-(beta Hydroxyethyl)-Anilin 
Min               Minutes 
mRNA          Messenger Ribonucleic acid 
PBS               Phosphate buffered saline 
PMSF            Phenylmethylsulfonyl fluoride 
SOCS-3         Suppressor of cytokine signaling 3 
TNFα            Tumor necrosis factor alpha 
WHO             World Health Organization 
 
 
 
 
 
 
 7
4  Introduction 
 
4.1 Obesity  
 
Obesity is one of the greatest public health challenges of the 21st century. It has reached 
epidemic proportions globally, with more than 1 billion adults being overweight – at least 300 
million of them clinically obese (Fig. 1). The prevalence of obese children and adolescents 
increased dramatically, affecting about 10 % of all children worldwide (1). However, the 
obesity epidemic is not restricted to industrialized societies, as obesity is often coexisting and 
developing faster in developing countries. Societal changes and worldwide nutrition transition 
are driving the epidemic with increased consumption of more energy-dense, nutrient-poor 
foods with high levels of sugar and saturated fats combined with less physical activity. 
 
                      
 
Fig 1: The global obesity problem (WHO, 2005) 
 
Obesity (from latin obesitas = fatness) is defined as a condition where excessive 
accumulation of body fat becomes a severe nuisance to our health (and quality of life) and 
reduces life expectancy. The prevalence of overweight and obesity is commonly assessed by 
using body mass index (BMI), defined as the weight in kilograms divided by the square of the 
height in metres (kg/m2). A BMI over 30 is defined as obese whereas a BMI over 40 means 
morbid obesity applying to both men and women and to all adult age groups (Table. 1). This 
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classification allows comparisons of weight status within and between populations and the 
identification of individuals and groups at risk of morbidity and mortality (2). Obesity causes 
or exacerbates many health problems. It is a major risk for serious diet-related chronic 
diseases, including type 2 diabetes, coronary heart diseases, certain forms of cancer, 
respiratory complications, and osteoarthritis of large and small joints. There is a close 
relationship between BMI and the incidence of several diseases, especially type 2 diabetes, 
wherein the risk is greatly increased for those subjects with a BMI above 29 (3).  
 
 
BMI WHO classification of BMI 
< 16,5  = underweight 
16,5 - 18,5 = meager 
18,5 – 25 = normal 
25 - 30 = overweight 
30 - 35 = moderate obese or obese I 
35 – 40 = severe obese or obese II 
40 - 50 = morbid obese or obese III 
> 50 = super obese 
 
Table 1: WHO classification of BMI 
 
 
4.2 Diabetes mellitus 
 
Diabetes mellitus has reached epidemic proportions and affects more than 200 million people 
worldwide. Moreover, the prevalence of diabetes for all age groups worldwide is projected to 
be doubled in 2030 (4). 
 
4.2.1 Definition of Diabetes mellitus  
 
Diabetes mellitus is a chronic disease that occurs when the pancreas does not produce enough 
insulin or when the body cannot effectively use the insulin it produces. A common effect of 
uncontrolled diabetes is raised blood sugar that over time leads to damages of nerves and 
blood vessels. Generally, two types of diabetes mellitus are defined (WHO, 2009): 
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 Type 1 diabetes (previously known as childhood-onset) is characterized by deficient 
insulin production and requires daily administration of insulin. Symptoms include 
excessive excretion of urine (polyuria), thirst (polydipsia), constant hunger, weight 
loss, vision changes and fatigue.  
 Type 2 diabetes (also called adult-onset) is based on the body’s ineffective use of 
insulin. It is largely the result of excessive body weight gain and physical inactivity. 
Approximately 85 % of people with diabetes are type 2, and of these, 90 % are 
overweight or obese. Until recently, this type of diabetes was confined to older adults 
but it is now also occurring in adolescents. Although lifestyle and overeating seem to 
be the triggering factors, genetic elements are also involved in the pathogenesis. The 
risk for type 2 diabetes has been calculated to be 38 % if one parent had this disease 
and is almost doubled if both parents are affected (5).  Symptoms are similar to those 
of type 1 diabetes, but are often less marked. As a result, type 2 diabetes may be 
diagnosed several years after onset.  
 Gestational diabetes is hyperglycaemia with onset or first recognition during 
pregnancy. 
 
 
4.2.2 Obesity and type 2 diabetes 
 
The likelihood of developing type 2 diabetes rises steeply with increasing                       
body fatness. Increased body fatness is accompanied by profound changes in physiological 
functions, especially with regard to whole body glucose homeostasis. It is characterized by 
elevated fasting plasma insulin and an exaggerated insulin response to an oral glucose load. 
On the basis of WHO recommendations from 1999, there are diagnostic criteria for diabetes 
mellitus, incorporating both fasting and 2-h after glucose load orally (75 g). With a fasting 
plasma glucose concentration of more than 6.7 mmol/l or with more than 11.1 mmol/l after 
two hours of glucose load, a diabetes mellitus is classified. If plasma glucose concentrations 
are below 11.1 but above 7.8 mmol/l, an impaired glucose tolerance is diagnosed.  
The mechanisms responsible for a normal glycaemia contain a balanced interplay between 
insulin secretion and insulin action. Insulin enhances glucose uptake by skeletal muscle, 
adipocytes and kidney cells and reduces glucose output by the liver. Therefore, 
hyperglycemia results either from decreased (absolute or relative) insulin secretion, e.g. due to 
beta cell dysfunction, or from reduced insulin action in target tissues, e.g. insulin resistance. 
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In addition, since insulin inhibits fatty acid release from adipose tissue, the lipolytic rate of 
adipose tissue is increasing causing elevated plasma levels of free fatty acids. In turn, the 
raised concentrations of glucose and fatty acids in the bloodstream will feed back to worsen 
both insulin secretion and insulin resistance. However, pancreatic beta cells often adapt to 
changes in insulin action. Between normal beta cell function and insulin sensitivity exist a 
curvilinear relation (6). Therefore, a decrease in insulin action is compensated by an 
upregulation of insulin secretion. Only in case of a deviation from this curvilinear relation, a 
deterioration of glucose tolerance will occur. In such patients, insulin secretion due to beta 
cell dysfunction is too low for a certain degree of insulin sensitivity/resistance. 
 
4.2.3 Long-term consequences of diabetes 
 
The risk of heart disease and stroke is increased in diabetic people: more than 50 % die of 
cardiovascular disease. In addition, longstanding diabetes may damage peripheral nerves 
(diabetic neuropathy) in more than half of the patients. Combined with reduced blood flow, 
neuropathy increases the chance of foot ulcers and eventually limb amputation. Diabetes is 
among the leading causes of kidney failure. 10 -20 % of diabetic people die of kidney failure. 
Long-term accumulated damage to the small blood vessels in the retina leads to diabetic 
retinopathy, the most important cause of acquired blindness in Western societies.  
 
4.2.4 Treatment of type 2 diabetes – relation to disease mechanisms 
 
The most efficient treatment remains weight reduction (diet, exercise, appetite modulators, 
and in severe forms bariatric surgery). Weight reduction leads in most patients to a profound 
improvement in glucose homeostasis. However, long-term weight reduction is often difficult 
to achieve. There are presently two main strategies to treat patients with overt type 2 diabetes 
in which weight reduction could not be achieved or was not sufficient: 1) increasing 
circulating insulin levels by either enhancing beta cell function or substitution with insulin, 
and/or 2) improving insulin sensitivity.  
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4.3 Insulin 
 
4.3.1 Insulin synthesis and secretion 
 
The hormone insulin is synthesized in β-cells of pancreatic islets. These islets have mainly 
endocrine functions and are named after its discoverer “islets of Langerhans”. Beside beta 
cells, they contain α-cells for glucagon secretion and δ-cells for somatostatin production. 
Furthermore, the pancreas has exocrine functions: it secretes digestive enzymes and 
bicarbonate into the intestinal lumen.  
 Insulin is generated from a proinsulin precursor molecule by the action of proteolytic 
enzymes which cleave the proinsulin at two sites, releasing the C-peptide (connecting peptide) 
and the mature insulin molecule. Insulin synthesis as well as the secretion of insulin from 
secretory granules, is stimulated by an increase in blood glucose concentration. Insulin and C-
peptide are released into the portal vein. Approximately 60 % of all insulin is removed in the 
first liver passage. In contrast, C-peptide is not extracted by the liver at all so that C-peptide 
levels are often measured to determine whole insulin production.  
 
4.3.2 Role of insulin 
Insulin regulates the energy and glucose metabolism in the body by stimulating common 
anabolic pathways. Insulin stimulates glucose uptake into muscle, fat and kidney cells from 
circulation as well as its storage in form of glycogen in liver and muscle. In the liver, insulin 
has four major effects. First, it promotes glycogen synthesis by enhancing the transcription of 
glucokinase and by activating glycogen synthase. Insulin inhibits also glycogen breakdown to 
glucose by reducing the activity of glycogen phosphorylase and glucose-6-phosphotase. 
Second, insulin promotes glycolysis and carbohydrate oxidation by increasing the activity of 
glucokinase, phosphofructase and pyruvate kinase. By inhibiting the activity of 
phosphoenolpyruvate carboxykinase and glucose-6-phosphotase, insulin inhibits 
gluconeogenesis. Third, insulin promotes the synthesis and storage of triglycerides by 
increasing the activity of acetyl CoA carboxylase and fatty acid synthase. Additionally, fat 
oxidation is inhibited indirectly causing increased levels of free fatty acids for re-esterification 
to triglycerides and storage in lipid droplets. Fourth, insulin enhances protein synthesis.  
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In skeletal muscle, insulin promotes glycogen synthesis from glucose by enhancing the 
transcription of hexokinase and by activating glycogen synthase. Most notably, glucose 
uptake is increased through recruitment of GLUT4 transporters to the plasma membrane. The 
increased activity of hexokinase, phosphofructokinase and pyruvate dehydrogenase enhances 
glycolysis and carbohydrate oxidation.  
In adipocytes, insulin promotes uptake of glucose and its conversion to triglycerides for 
storage. To this end, recruitment of GLUT4 transporters is promoted. In addition, 
enhancement of glycolysis leads to the formation of α-glycerol-phosphate which is esterified 
with free fatty acids to triglycerides. At the same time, insulin inhibits lipolysis by decreasing 
the activity of hormone sensitive triglyceride lipase to block the breakdown of triglycerides. 
Additionally, insulin promotes the conversion of pyruvate to free fatty acids by stimulating 
pyruvate dehydrogenase and acteyl CoA carboxylase. Free fatty acids are also released from 
triglycerides contained in chylomikrones and VLDL by insulin-stimulated lipoprotein lipase. 
 
4.3.3 Insulin signalling and insulin resistance 
 
Insulin signalling is initiated with the binding of insulin to its receptor, a tyrosine kinase 
receptor. Activation of the tyrosine kinase results in the addition of a phosphate molecule to 
particular tyrosine residues (phosphorylation) on "substrate" proteins such as the insulin 
receptor substrate 1 (IRS-1). SH-2 containing proteins (e.g. phospatidylinositol 3-kinase) dock 
onto certain phosphorylated tyrosine groups on the IRSs, and thus become activated. 
Activation of phosphatidyl inositol 3-kinase (PI-3-K) phosphorylates phosphatidyl inositol-
4,5-biphosphate (PIP2), to form phosphatidyl inositol-3,4,5-trisphosphate (PI-3,4,5-P3), which 
in turn activates phosphatidyl inositol-dependent kinase (PDK). PDK is finally activating 
PKB activates the serine/threonine protein kinase Akt (also called  protein kinase B, PKB) as 
well as the atypical protein kinase C isoforms  and  which leads to the insertion of GLUT4 
glucose transporters into the plasma membrane enhancing glucose uptake. In addition, PDK 
also phosphorylates and, thus, inactivates glycogen synthase kinase-3 (GSK-3). By inhibiting 
this kinase, glycogen synthesis is enhanced by insulin. Moreover, PDK activates mTOR 
(target of rapamycin), which promotes the translation of mRNA into protein. Moreover, 
activation of the insulin signaling pathway stimulates enzymes involved in lipid metabolism 
or the MAP kinase pathway being responsible for gene expression and growth.  
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In states of insulin resistance, insulin signaling may be negatively modulated on different 
levels. Inhibitory triggers, like inflammatory cytokines, adipokines as well as high glucose 
and non esterified fatty acids (NEFA) levels, affect their respective signal modulators and 
consequently inhibit propagation of the insulin signal. For example, the proinflammatory 
cytokine interleukin 6 enhances expression of SOCS-3, which in turn degrades IRS proteins 
(7). 
 
4.4 Adipose tissue 
 
The adipose tissue has a major role in the regulation of nutrient and energy homeostasis. In 
addition, it is involved in the modulation of immune responses, reproductive function, 
haemostasis, mechanical support, bone mass growth and thermogenesis. There are two types 
of adipose tissue depending on its cell structure, location, colour, vascularisation and function: 
white adipose tissue (WAT) and brown adipose tissue (BAT). WAT represents the vast 
majority of adipose tissue in the organism and is the site of energy storage, whereas BAT 
contains a large number of mitochondria and is specialized in heat production and energy 
expenditure (8)  particularly in small mammals and human neonates. 
Adipose tissue consists of a large number of adipocytes (the main cellular component), other 
non-fat cells, connective tissue matrix, vascular and neural tissues. The non-adipocyte cellular 
component includes inflammatory cells (macrophages), immune cells, preadipocytes and 
fibroblasts. Adipocytes constitute the main storage depots of the energy in form of 
triglycerides droplets. Conversely, they catabolise triglycerides in order to release glycerol 
and fatty acids that participate in glucose metabolism in liver and other tissues. As adipocytes 
grow larger (hypertrophic), they become dysfunctional and insulin resistant, resulting in an 
increased release of free fatty acids.  
 
4.4.1 Adipose tissue as an endocrine organ 
 
Adipose tissue is not only known for its capacity to store the excess of dietary intake as 
triglycerides. Furthermore, adipose tissue is the largest endocrine organ in the body, secreting 
adipokines (i.e. hormone-like factors released by the adipose tissue), cytokines and other 
proteins with specific biological functions. One of the best studied adipokine is leptin 
discovered in 1994. Leptin levels correlate directly with adipose tissue mass (9) and it 
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influences body weight, food intake, and fat stores via the hypothalamus. Leptin has been 
shown to modulate the activity of different subtypes of hypothalamic neurons bearing leptin 
receptors, thereby reducing food intake and increasing energy expenditure. In fact, mice with 
a mutation in the leptin (ob/ob mice) or leptin receptor (db/db mice) gene, as well as human 
subjects with mutations in the same genes, are massively obese (10). Another important 
adipokine is adiponectin which enhances insulin sensitivity. Moreover, it increases fatty acid 
oxidation in liver and skeletal muscle promoting lipid catabolism and decreasing triglyceride 
storage. In addition, it was reported to decrease the expression of adhesion molecules within 
the vascular wall, resulting in a decreased atherogenic risk. In humans, the role of the 
adipokine resistin is controversial whereas in mice it is known to induce glucose intolerance 
and insulin resistance. Probably it decreases the activity of AMP-activated protein kinase and 
increases the expression of gluconeogenic enzymes in the liver (8). 
 
4.4.2 Adipose tissue as an initiator of inflammatory response 
 
Obesity is associated with the recruitment of bone marrow-derived macrophages into adipose 
tissue. These adipose tissue macrophages (ATMs) are a major source of proinflammatory 
cytokines and chemokines, recruiting additional macrophages and propagating the chronic 
inflammatory state. Released proinflammatory cytokines including TNFα, IL-1β and IL-6 
may profoundly alter adipocyte function resulting in altered secretion patterns of adipokines 
and cytokines as well as an increased release of free fatty acids. Consequently, insulin 
resistance may develop both locally, i.e. in adipose tissue, as well as systemically. Consistent 
with such notion, elevated levels of proinflammatory cytokines such as TNFα and IL-6 as 
well as of free fatty acids have been shown in individuals with insulin resistance and diabetes. 
 
4.4.3 Distribution and localization of adipose tissue 
 
Adipose tissue distribution may vary in obese people. In general, two different phenotypes of 
fat distribution are defined: increased accumulation of subcutaneous adipose tissue in the hip 
and thigh region (often referred as gynoid type or pear-shaped type of obesity) or increased 
accumulation of mainly visceral and upper thoracic adipose tissue (android type or apple-
shaped type of obesity). Normally it does not exist only one phenotype, often one type is 
dominating. Especially the accumulation of visceral adipose tissue constitutes a 
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cardiovascular risk factor and is often associated with metabolic anomalies, like insulin 
resistance, arterial hypertension and dyslipidemia (11). 
Visceral adipose tissue in humans include mesenteric as well as omental adipose tissue and is 
by definition drained to the portal vein whereas subcutaneous adipose tissue as well as 
perirenal adipose tissue is drained to the caval vein. As a consequence, factors released by 
portal drained adipose tissue, like FFAs, cytokines and adipokines are delivered directly into 
the liver where they are supposed to induce hepatic insulin resistance and/or steatosis. In 
rodents, a unique fat pad is found intra-abdominal closely located to the gonads (perigonadal 
or epididymal (in male mice) fat depot). This fat pad is drained to the vena cava inferior. An 
overview of different adipose tissue depots is shown in a mouse model (Fig. 2). 
 
 
 
 
 
Subcutaneous white adipose tissue 
i    Anterior white adipose tissue 
ii   Inguinal adipose tissue 
 
Intra-abdominal visceral white adipose tissue 
iii  Mesenteric adipose tissue 
iv  Retroperitoneal adipose tissue 
v   perinephric  
vi  perigonadal adipose tissue 
 
Brown adipose tissue 
vii interscapular brown adipose tissue 
viii mediastinal adipose tissue 
Fig.  2: The white subcutaneous, intra-abdominal visceral and brown adipose tissue depots are 
shown in a mouse model. Adapted from Murano, I. et al. Adipocytes 1, 121–130 (2005).  
In the literature, intraabdominal adipose tissue is often used synonymously for visceral 
adipose tissue. However, as explained above, visceral adipose tissue in its proper sense 
includes only those intra-abdominal fat pads that are drained to the portal vein.  
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4.4.4 Characteristics of visceral and subcutaneous adipose tissue 
 
Adipocytes from visceral adipose tissue (VAT) are morphologically and functionally different 
from subcutaneous adipose tissue (SAT). Fatty acid turnover and lipolysis are higher in 
visceral adipocytes and these cells are less responsive to the antilipolytic effect of insulin. 
Moreover, in contrast to subcutaneous fat cells, visceral fat cells express higher glucocorticoid 
receptor levels and respond to glucocorticoids with lipoprotein lipase activation (12). Among 
hormones secreted by adipocytes, leptin levels are more closely correlated with subcutaneous 
than with visceral fat.  
There are also different aspects concerning proinflammatory cytokines, for example their 
expression levels in different fat depots (13). TNFα was shown to be involved in adipocyte 
metabolism by suppressing the expression of many adipose-specific genes, such as lipoprotein 
lipase, and by stimulating lipolysis, leading to decreased triglyceride accumulation in 
adipocytes. Expression levels of TNFα were often shown to be equal in VAT and SAT. 
However, it was shown that mRNA expression of the inflammatory cytokine Interleukin-6 is 
higher in VAT. IL-6 stimulates acute-phase proteins and activates the hypothalamus-pituitary-
adrenal axis. IL-6 plasma levels are proportional to fat mass, whereas they are higher secreted 
from VAT than in SAT (14). In liver, IL-6 impairs insulin signalling through the induction of 
SOCS-3 expression and is often discussed to contribute to hepatic insulin resistance (15). The 
monocyte chemo-attractant protein-1 (MCP-1) has an essential role in the recruitment of 
macrophages to adipose tissue. In obese patients its expression is increased in adipose tissue 
when compared to lean individuals. Commonly, VAT is more infiltrated with inflammatory 
cells and is more capable of generating those proteins than SAT (16). 
 
4.5 The portal theory associated with visceral fat accumulation 
 
Visceral obesity has been often linked with insulin resistance, glucose intolerance, 
dyslipidemia, and cardiovascular disease. Especially, the liver has been implicated as a 
primary site for the development of insulin resistance associated with visceral obesity. As 
explained above, obesity is associated with increased release of proinflammatory cytokines 
and free fatty acids as well as altered production of adipokines. In the case of visceral obesity, 
the liver is directly exposed to these factors since they were released into the portal vein. As a 
consequence, hepatic insulin resistance as well as hepatic steatosis (lipid accumulation) 
occurs. Such hypothesis is often referred as the “portal hypothesis”. This means that chronic 
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exposure of the liver to elevated FFAs would promote liver gluconeogenesis, deplete enzymes 
involved in FFA oxidation, and increase hepatic lipogenesis (17). In addition, elevated FFA 
levels are known to increase liver triglyceride content and decrease insulin clearance, both of 
which are associated with insulin resistance. The higher lipolytic capacity in visceral 
adipocytes with its greater sensitivity to beta adrenergic stimulation and its lower sensitivity 
to the anti-lipolytic effect of insulin, enforce additional fatty acid flux to the liver (11). 
Moreover, different cytokines were shown to impact on hepatic insulin sensitivity. For 
instance, there are several studies supporting a role of IL-6 to inhibit insulin signalling in the 
liver (15, 18), likely through the induction of SOCS-3 expression leading to inhibition of IRS-
1 activation (19-21).  
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5  Aims of the study 
 
To determine the effects of excessive adipose tissue on whole-body glucose and energy 
homeostasis a novel fat tissue transplantation paradigm was used.  
We hypothesized that beneficial and adverse effects of adipose tissue on whole-body glucose 
and energy homeostasis depend on venous drainage of adipose tissue, changes in 
adipokine/cytokine profile and alterations in food intake and/or energy expenditure.  
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6  Methods 
 
6.1 Animals  
 
Male C57BL6JOlaHsd mice were purchased from Harlan Netherlands (Horst, The 
Netherlands) and male IL-6 KO mice and their respective wild-type mice were from Charles 
River Laboratories (Wilmington, MA, USA). AFasKO mice were produced as described 
previously (21). All mice were housed in a pathogen-free environment on a 12-h light-dark 
cycle, with free access to standard rodent diet (Provimi Kliba, Kaiseraugst, Switzerland). All 
protocols conformed to the Swiss animal protection laws and were approved by the Cantonal 
Veterinary Office in Zurich, Switzerland. 
 
6.2 Surgical procedure for portal and caval transplantation 
 
Transplantation procedure was performed at 6 weeks of age. Mice were anaesthetized with 
isoflurane (Abbott, Baar, Switzerland). Both epididymal fat pads were removed from the 
donor mouse, weight and rinsed with 0.9% saline. Both pads were stitched to the visceral side 
of the peritoneum (caval transplantation) or to the mesenterium of the recipient mouse (portal 
transplantation) using Monocryl 6.0 (Johnson-Johnson, Spreitenbach, Switzerland). At the 
end of surgery, peritoneum was closed with Vicryl 5.0 (Johnson-Johnson, Spreitenbach, 
Switzerland) and the skin was stapled (3M Health Care, Neuss, Germany). Sham-operated 
control mice received the same treatment, but instead of the fat pad transplantation, an 
artificial suture was performed with Vicryl 5.0. Subcutaneous injection of buprenorphine 
every 12 h for 2 days was used for analgesia. In order to prevent transplant rejection, donor 
and recipient mice were littermates. 
 
6.3 Hyperinsulinemic-euglycemic clamps 
 
The hyperinsulinemic-euglycemic clamp technique is presently the “gold standard” for 
measuring insulin sensitivity in vivo. During clamping, insulin is infused via a catheter 
intravenously to raise the insulin concentration to supraphysiological levels. At the same time, 
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glucose is infused to maintain blood glucose at euglycemic levels (5-6 mmol/l; “clamping” of 
blood glucose levels) (22). 
Seven days before clamping, mice are anesthetized with isofluran and a catheter (MRE 025, 
Braintree Scientific, Braintree, MA, USA) is inserted into the left jugular vein and 
exteriorized at the back of the neck. Upon recovery, only mice that have regained > 90 % of 
their preoperative weight are studied. After a fasting period of five hours, 3-[3H] glucose   
(3H-G) (0.1µCi/min; PerkinElmer, Schwerzenbach, Switzerland) is infused for 80 min and a 
blood sample is collected from the tail tip for basal turnover calculation. After basal sampling, 
insulin (18 mU/kg x min) is infused for 90 min. Euglycemia is maintained by periodically 
adjusting a variable infusion of 20 % glucose with a syringe pump (TSE systems, Bad 
Homburg, Germany). The glucose infusion rate is calculated as the mean of the steady state 
infusion which reached after about 60 min of insulin and glucose infusion (Fig. 3). A blood 
sample is collected after steady state infusion. The glucose turnover rate is calculated by 
dividing the rate of 3H-G infusion by the plasma 3H-G specific activity. Hepatic glucose 
production is calculated by subtracting the glucose infusion rate from the glucose turnover 
rate (23). 
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Fig. 3:  Blood glucose concentrations and glucose infusion rate during hyperinsulinemic-
euglycemic clamp. After a prime infusion of 3-[3H]-glucose for 80 min, insulin and 3-[3H]-
glucose are infused via catheter into jugular vein (time point 0 min). Left graph: Blood 
glucose levels during a hyperinsulinemic-euglycemic clamp of Sham operated () and mice 
receiving portal drained fat pads (). Blood glucose levels were clamped upon insulin 
infusion between 5 and 6 mmol/l. Right graph: To maintain euglycemia, increasing amounts 
of glucose needs to be infused. Glucose infusion rates increase until a “steady state” infusion 
is reached after about 60 min. Steady state glucose infusion is calculated as the mean infusion 
rate between 60 and 90 min.  
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 6.4 Glucose tolerance tests 
 
For the intraperitoneal glucose tolerance test (ipGTT) mice were fasted overnight (12 hours).  
Glucose (2g/kg body weight) was injected intraperitoneally and blood was collected from the 
tail vein at 0, 15, 30, 45, 60, 90 and 120 min after glucose administration (24). Plasma glucose 
was measured using a glucose meter (Ascensia Contour; Bayer, Zurich, Switzerland). 
 
6.5 Insulin tolerance tests 
 
For the intraperitoneal insulin tolerance test (ipITT) mice were fasted for fed and then fasted 
for three hours. Human normal insulin (0.75 U/kg body weight) were injected 
intraperitoneally and blood was collected from the tail vein at 0, 15, 30, 45, 60, 90 and 120 
min after insulin administration. 
 
6.6 Analyses of plasma samples 
6.6.1 Determination of IL-6 in systemic and portal plasma 
 
Systemic blood was collected by aspirating blood from the heart and for portal blood the 
portal vein was punctured after 3-5 h of fasting. Blood was centrifuged immediately with 
8000 rpm for 10 min. Plasma IL-6 levels were determined with mouse LINCOplex kits from 
Linco Research, Inc. (Labodia, Yens, Switzerland). The kit is based on Luminex 
xMAPtechnology (Linco Research, St Charles, MI, USA) and use microsphere bead sets that 
are uniquely labelled with a mixture of two fluorescent dyes. The captured antibodies specific 
for each analyte are covalently coupled to individual bead sets. At the time of the assay, a 
mixture of beads is incubated overnight at 4°C with 10 μl of standards or mouse plasma 
samples in a 96-well filterbottom plate. On the next day, the beads are washed, and 
biotinylated detection antibody cocktail is added and incubated for 30 min at room 
temperature, followed by the addition of streptavidin-phycoerythrin and incubation for 
another 30 min. After a final wash, the resuspended beads are read on a Luminex 100 reader 
(Bio-Rad Laboratories, Hercules, CA, USA) and the concentration of each analyte in the 
samples to be tested is determined on the basis of individual standard curves. 
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6.6.2 Determination of plasma leptin and adiponectin  
 
Blood samples were obtained from the tail vein of mice after overnight fasting. 
Concentration of leptin and adiponectin was determined with mouse LINCOplex kits from 
Linco Research, Inc. (Labodia, Yens, Switzerland). 
 
6.6.3 Determination of Non Esterified Fatty Acid (NEFA) in plasma samples             
 
Systemic blood was collected by aspirating blood from the heart and for portal blood the 
portal vein was punctured after 3-5 h of fasting. Blood was centrifuged immediately with 
8000 rpm for 10 min. NEFA levels were measured using the ACS-ACOD-MEHA method 
(Wako Chemicals GmbH, Neuss, Germany). 
 
6.6.4 Determination of plasma insulin   
 
Plasma was collected from the tail vein of mice after overnight fasting. Insulin was 
determined using an ELISA kit (Ultra Sensitive Rat Insulin ELISA; Crystal Chem, Downers 
Grove, IL, USA).  
 
6.7 Total liver lipid extraction 
 
Liver tissue (30mg) was homogenized in PBS and lipids were extracted in a chloroform-
methanol (2:1) mixture. Total liver lipids were determined by a sulfphosphovanillin reaction 
as described by  (25). 
 
6.8 RNA extraction and quantitative reverse transcription-PCR (RT-PCR) 
 
Total RNA from fat pads respectively liver tissue was extracted with the RNeasy lipid tissue 
mini kit (Qiagen). First strand cDNA synthesis was performed using Superscript III Reverse 
Transcriptase and random hexamer primer. Typically 0.75 µg of total RNA, 0.1 µl of random 
hexamer primer and 1 µl dNTPs (10mM) were adjusted with water to 13 µl and incubated at 
65°C for 5 min in order to dissolve secondary structures of the RNA. After incubation on ice 
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for 1 min, 4 µl 5x first strand buffer, 1 µl 0.1M DTT, 1 µl RNase inhibitor and 1 µl 
Superscript III Reverse Transcriptase were (all reagents from Invitrogen, Basel, Switzerland) 
added to 13 µl reaction mix. Incubation circle started with 25°C for 5 min, followed by 50°C 
for 60 min and 70°C for 15 min. At the end, cDNA samples were stored at -80°C. 
Taqman system (Applied Biosystems) was used for real-time PCR amplification. The cDNA 
samples were diluted 1/5 and 18S RNA (Applied Biosystems) for negative control was diluted 
1/10 in water. Samples were loaded on a 96-well reaction plate (MicroAmp, Applied 
Biosystems, USA) containing 10 µl Universal PCR Mastermix (Taqman, Apllied Biosystems, 
USA), 1 µl of specific primer or 18S RNA, 7 µl water and 2 µl of diluted cDNA.  The 
detection of the amplification was performed with the 7500 Fast Real-Time PCR System 
(Applied Biosystems, USA). Relative gene expression was obtained after normalization to 
18sRNA, using the formula 2-ΔΔcp (26). The following primers were used: TNF-α 
Mm00443258_m1, IL-6 Mm00446190_m1, KC Mm00433859_m1, IL-1β 
Mm0043422/8_m1, MCP-1 Mm00441242_m1, Fas Mm00433237_m1, FasL 
Mm00438864_m1, cd11c Mm00498698_m1, Hif-1α Mm00468869_m1, SOCS3 Mm 
00545913_s1, CD68 Mm03047343_m1, F4/80 Mm00802529_m1, cd11b Mm00434455_m1 
(Applied Biosystems).   
 
6.9 Western Blot 
 
Tissue samples were pulverized in liquid nitrogen and homogenized in a buffer containing 
150 mM NaCl, 50mM Tris-HCl (pH 7.5), 1mM EGTA, 1% NP-40, 0.25% sodium 
deoxycholate, 1mM sodium vanadate, 1mM NaF, 10mM sodium β-glycerophosphate, 100nM 
okadaic acid, 0.2mM PMSF and a 1:1000 dilution protease inhibitor cocktail (Sigma). Protein 
concentration was determined using conventional bicinchoninic acid (BCA) protein assay kit 
(Pierce, Rockford, USA) and equivalent amounts of protein (20-50μg) were resolved by LDS-
PAGE (4-12% gel; NuPAGE, Invitrogen). Proteins were transferred to a nitrocellulose 
membrane (0.2μm, BioRad) and blocked for one hour in 5% non fat dry milk (BioRad) 
resolved in Tris buffered saline, containing 1% Tween 20. Membranes were incubated over 
night at 4°C on a rocking platform with respective primary antibodies. The following primary 
antibodies were used: anti-phospho-Akt (S473) and anti-Akt (Cell Signaling). Subsequently, 
membranes were incubated with secondary antibody (horseradish peroxidase-conjugated; 
Santa Cruz Biotechnology, and Alexis Biochemicals) for 1 hour at room temperature. Bands 
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were detected after 5 minute incubation with Lumi-Light substrate (Roche). Membranes were 
exposed in an Image Reader and analyzed with Image Analyzer (FujiFilm). 
 
6.10 Histology  
 
Five weeks after transplantation liver tissue was fixed in 4% buffered formalin and imbedded 
in paraffin. Tissue sections (4 µm) were deparaffinised with xylol (two times 10 minutes), 
rehydrated with 100, 95, 70 % ethanol (5 minutes each) and rinsed with dest. water. Sections 
were stained with haematoxylin for 10 minutes, washed and then put very shortly in 
ethanol/HCl. After washing for 10 minutes, sections were stained with Eosin (1 min). 
Sections were washed again and then shortly put in 70, 95, 100% ethanol and finally two 
times in xylol. Sections were mounted with Pertex (Histo-Lab, Goteborg, Sweden). Pictures 
were taken with Axioplan 2 microscope (Zeiss) and Axio Vision software (Carl Zeiss Image) 
with a 20x magnification.  
 Fat tissues were fixed in 4% buffered formalin and imbedded in paraffin. Sections were 
obtained either at the time of sacrification and stained with Hematoxylin/Eosin. For each fat 
pad of a mouse at least 100 adipocytes were analyzed. Images were analyzed using ImageJ 
software for quantification (National Institutes of Health, Bethesda, MD). Macrophage 
number was determined by Immunohistochemistry. For this fat tissue sections were 
deparaffinised and then given for 30 min in 0.3 % H2O2 in methanol. Sections were washed in 
PBS and incubated in normal serum to reduce non-specific background staining. Sections 
were incubated with the mac2 antibody (Cedarlane, Ontario, Canada) overnight at 4°C. After 
washing with PBS, sections were incubated with biotinylated secondary antibody for 30 min 
at room temperature. Sections were washed again and then incubated with ABC complex 
(ABC Kit Vectostain, Vector laboratories, Burlingame, USA). After washing, DAB (Zymed 
laboratories, Invitrogen, Carlsbad, USA) was used for histoenzymatic visualization. Mac2 
positive cells were counted per nuclei of seven randomly selected fields per section containing 
at least 90 cells. 
 
6.11 Indirect calorimetry, physical activity and ingestive behavior 
 
For energy expenditure (EE) and respiratory quotient (RQ) determination, mice were 
individually housed in plexiglass air-tight cages designed for open circuit calorimetry 
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(AccuScan Inc., Columbus, OH, USA).  Group sizes were: sham (n=5), systemic drainage 
(n=5), and portal drainage (n=6).  Using Integra ME 2.21 software (AccuScan, Inc.), oxygen 
and carbon dioxide levels in each chamber were measured for 30 seconds every 5 minutes.  
Based on these values, EE and RQ were calculated according to (27) and used to determine 
average hourly and light- and dark-phase EE and RQ.  The system simultaneously measured 
physical activity and food and water intake. For metabolic cages, mice were fed a standard 
powder chow containing 3.2 kcal/g (3433, Provimi Kliba AG, Kaiseraugst, Switzerland). 
Horizontal activity was determined by number of breaks in infrared photobeams that cross the 
cage in a 2D grid.  For food and water intake measurements, each cage was equipped with a 
food hopper and water bottle placed on a scale that continuously monitored mass to the 
nearest 0.01g. Data were collected for four 22-hour days.  Data from each animal was 
averaged over the four days to calculate representative values for each mouse used for 
statistical analysis. 
 
6.12 Data analysis 
 
Data are presented as means +/- SEM and were analyzed by Student’s t test or analysis of 
variance (ANOVA) with a Turkey correction for multiple group comparisons respectively 
Bonferroni’s post-hoc test for individual comparisons. A p-value < 0.5 was considered 
statistically significant. The software in use was Prism Version 5.0 (GraphPad Software Inc., 
San Diego, CA, USA). 
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7  Results 
 
7.1 The impact of fat tissue localization and its venous drainage on glucose  
      homeostasis 
 
 
To estimate the potential metabolic effects of an artificial increase in fat tissue mass 
epididymal fat pads of a regular chow-fed donor mouse were transplanted to the peritoneum, 
resulting in systemically (via vena cava) drained transplants, or to the mesenterium, resulting 
in portally drained transplants, of a chow-fed littermate mouse. At the time of sacrifice (five 
weeks after transplantation), transplanted fat pads were adherent and well vascularised (Fig. 
3A). Sham operation as outlined above was performed in control littermates. Mice tolerated 
the surgical procedure and the fat transplantation well - no adverse events were noted. In 
order to confirm venous drainage of transplanted fat pads to the portal vein, Evans Blue was 
injected retrogradely into the portal vein. As depicted in Fig. 3B, transplanted fat pads were 
stained with Evans Blue as was endogenous mesenteric fat tissue, but not caval-drained 
epididymal fat tissue, confirming the portal drainage of the mesenteric-transplanted fat tissue.  
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Fig. 3: Transplantation was performed at 6 weeks of age. Both epididymal fat pads were 
removed from a donor mouse and stitched to the peritoneum (cTx; left panel) or mesenterium 
(pTx; right panel) of a littermate recipient. (A) Six weeks after transplantation, the abdominal 
cavity was opened and the transplanted fat pad was visualized. (B) To confirm portal drainage 
of transplanted fat pads, Evans Blue dye (5mg/ml) was injected into the portal vein.  
 
 
We have previously shown that mice receiving fat pads drained to the inferior  vena cava  had 
improved glucose tolerance (24). Four weeks after transplantation, body weight gain was not 
different between sham-operated mice and mice receiving a portal-drained fat transplant 
(3.0±0.4 g vs. 2.9±0.5 g; p=0.85). However, as depicted in Fig. 4A, increase in blood glucose 
concentrations after an intraperitoneal glucose load was significantly higher in mice receiving 
a fat transplant drained to the portal vein (portal-drained fat pad transplantation; pTx) 
compared to mice receiving caval-drained fat pad transplantation (cTx) as well as to sham-
operated mice, indicating impaired glucose tolerance in mice receiving a portal drained fat 
pad transplant (Fig. 4A). To examine the potential role whether the transplantation procedure 
on its own deteriorates glucose homeostasis, for example, by altering the delivery of 
inflammatory mediators from the GI-tract, peritoneal tissue containing no adipocytes was 
transplanted to the mesenterium. As depicted in Fig. 4B, glucose tolerance was not impaired 
in such transplanted mice (Fig. 4B). 
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Fig. 4: Intraperitoneal glucose tolerance test (2 g glucose/kg body weight) was performed 
four weeks after surgical procedure in mice receiving portal drained transplants (pTx; ), in 
mice receiving caval drained transplants (cTx; ) or in sham-operated mice () after a 
overnight fast. Results are expressed as mean blood glucose concentration (left panel) or area 
under curve (right panel) ± SEM of 5 (pTx), 15 (cTx) or 25 (Sham) animals. **p < 0.01, #p < 
0.001 (ANOVA). (B) Intraperitoneal glucose tolerance test (2 g glucose/kg body weight) was 
performed four weeks after surgical procedure in mice receiving portal drained peritoneal 
tissue transplants (perit pTx; ) or in sham-operated mice () after a overnight fast. Results 
are expressed as mean blood glucose concentration ± SEM of 2 animals. 
 
To determine whether the effect on glucose homeostasis of one transplantation site 
predominates over the other, a double transplantation approach was performed, i.e. one 
epididymal fat pad of the donor mouse was stitched to the peritoneum (and, thus, drained to 
the inferior caval vein), the other pad was stitched to the mesenterium (and, thus, drained to 
portal vein). Transplanted fat pads were similar in size and originated from the same donor 
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mouse, which was a littermate of the recipient mouse. As depicted in Fig. 5 glucose tolerance 
in such transplanted mice was not different form sham-operated mice four weeks after 
surgery.  
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Fig. 5: Both epididymal fat pads were removed from a donor mouse. One was stitched to the 
peritoneum and the other to the mesenterium of the same littermate (dTx). Intraperitoneal 
glucose tolerance test (2 g glucose/kg body weight) was performed four weeks after surgical 
procedure in mice receiving a double transplant (dTx; ), in mice receiving a portal-drained 
transplant (pTx) or in sham-operated mice () after a overnight fast. Results are expressed as 
mean blood glucose concentration ± SEM of 3-8 animals. 
 
We next assessed adipose tissue morphology of endogenous and transplanted fat pads in 
sham-operated and portal transplanted (pTx) mice. Adipocytes in portal transplanted fat pads 
were similar in size as endogenous mesenteric adipocytes but smaller than endogenous 
epididymal adipocytes (Fig. 6A, B). In addition, macrophage infiltration rate was much higher 
in portal transplanted compared to endogenous fat pads and sham-operated endogenous 
epididymal fat pads (Fig. 6C).  
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Fig. 6: (A) Representative, Hematoxylin and Eosin-stained histological sections of 
endogenous epididymal, endogenous mesenteric or transplanted fat pads from sham-operated 
mice and pTx mice are shown 5 weeks after transplantation. Adipocyte cell perimeter was 
measured using ImageJ. (B) Up to 100 cells for each fat pad were analysed and the results 
represent the mean ± SEM of three or four different mice. All values are expressed relative to 
the adipocyte cell perimeter of endogenous epididymidal fat pad of sham-operated mice. 
Black bar: sham-operated mice; white bar: mice receiving a portal fat transplant. (C) 
Histological sections of endogenous epididymal and portal transplanted tissue were 
immunostained with mac2 antibody. Mac2 positive cells were counted in seven randomly 
selected fields per section (about 90 cells) and expressed relative to total cell nucleus content. 
Results represent the mean ± SEM of four different mice.  
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Consistent with the portal theory, we hypothesized that portal-drainage of fat transplant would 
cause hepatic insulin resistance. To assess this possibility a hyperinsulinemic-euglycemic 
clamp was performed five weeks after surgery. Glucose infusion rate was significantly lower 
in portal transplanted mice compared to sham-operated mice (Fig. 7A and Fig. 3). Moreover, 
during hyperinsulinemic-euglycemic clamp, insulin-induced suppression of hepatic glucose 
production was blunted in mice receiving a portal-drained fat pad transplant, but was clearly 
evident in sham-operated mice (Fig. 7B). Therefore, mice receiving portal drained fat pad 
transplants drained to the portal vein developed hepatic insulin resistance. Furthermore, 
insulin-induced phosphorylation of Akt was markedly reduced in livers of portally 
transplanted mice compared to that of sham-operated mice (Fig. 7C, left panel). This eminent 
reduction in hepatic insulin signaling confirmed the development of hepatic insulin resistance 
in portally transplanted mice. In contrast, glucose disposal rate as well as insulin signaling in 
skeletal muscle were not affected by the portal-drained transplant (Fig. 7C, right panel), 
suggesting maintained insulin-sensitivity of skeletal muscle.  
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Fig. 7: Hyperinsulinemic-euglycemic clamps were performed 5 weeks after transplantation. 
(A) Glucose infusion rate was adjusted to a blood glucose level of 5 mM and kept constant for 
at least 20 min. (B) Hepatic glucose production (HGP) were calculated in the basal period and 
in response to insulin infusion (18 mU/kg/min) during the clamp study. Results are the mean 
± SEM of 5 animals. *p < 0.05 (Student’s t test). (C) Insulin (1U/kg) was injected i.p. in 
overnight fasted mice 5 weeks after transplantation. Liver and skeletal muscle samples were 
harvested 15 minutes later and phosphorylation of Akt at S473 was determined by Western 
blotting. A representative blot is shown in the upper panel. Results are the mean ± SEM of 3 
animals. **p < 0.01 (Student’s t test).  
 
 
The development of hepatic insulin resistance is often associated with hepatic steatosis and 
Kupffer cell activation (28). Thus, hepatic lipid contents as well as expression levels of tissue 
macrophage markers were assessed. Histological examinations and biochemical determination 
of total hepatic lipid content was similar in sham-operated and portal transplanted mice (Fig. 
8A/B). Moreover, no increased infiltration/activation of hepatic Kupffer cells was detected 
(Fig. 8C). Consistent with the absence of hepatic steatosis in portal transplanted mice, no 
differences in systemic and portal plasma free fatty acids (FFA) levels were found in both 
groups of mice (Fig. 8D). Thus, transplantation of fat pads to sites drained by the portal vein 
induces hepatic insulin resistance independently of hepatic steatosis and Kupffer cell 
infiltration/activation.  
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Fig. 8: (A) Hematoxylin and Eosin-stained liver sections from sham-operated and pTx mice. 
(B) Total liver lipids were determined and expressed relative to liver weight. Results represent 
the mean ± SEM of 4 to 6 mice of each group. (C) mRNA expression of indicated markers 
was analyzed in liver tissue of sham-operated and pTx mice. Results are the mean ± SEM of 5 
mice per group, expressed relative to WT and normalized to expression of 18S. (D) FFA 
levels were determined in systemic and portal plasma samples of mice receiving a portal 
drained fat transplant (pTx) and in sham-operated mice after 3 hours of fasting. Results are 
the mean ± SEM of 5-6 animals.  
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To investigate potential mediators of hepatic insulin resistance observed in mice receiving 
portal-drained transplant. Transplanted fat tissue may not acquire the exact biological function 
as the endogenous fat tissue of the same depot, and its function may be affected by a 
combination of host and donor factors. Thus, to determine potential differences between caval 
and portal transplanted fat pads, we utilized endogenous and transplanted fat depots from the 
double transplanted mice. Such approach allowed us to exclude different host factors, as well 
as secondary metabolic effects induced by cTx versus pTx, as shown in Fig. 3. As depicted in 
Fig. 9A, transplanted fat tissue of either localization exhibited a much more inflammatory 
gene expression profile than endogenous epididymal fat pads, as assessed by mRNA 
expression of pro-inflammatory cytokines and cd11c. Yet intriguingly, when comparing 
portal transplanted to caval transplanted fat pads, the former exhibited higher expression 
levels of IL-6 and Fas ligand (FasL).  
Since IL-6 was previously associated with hepatic insulin resistance (20-21) we postulated 
that increased IL-6 expression and secretion from portal transplanted fat pads might be 
responsible for hepatic insulin resistance. Thus, IL6 was determined in systemic and portal 
vein plasma samples of sham-operated and portal transplanted mice. Systemic and portal IL-6 
plasma levels were similar in sham-operated mice, whereas IL-6 concentration was more than 
70% higher in portal compared to systemic blood samples of mice receiving a portal drained 
fat transplant (Fig. 9B). Even though this difference was not significant these data suggest 
increased delivery of IL-6 to the liver of mice receiving a portal transplant, potentially 
originating from the transplanted fat pad. Consistent with an increased delivery of IL-6 to the 
liver, hepatic SOCS3 mRNA expression, which is induced by IL-6 (7), was enhanced in mice 
receiving a portal transplanted fat pad (Fig. 9C).  
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Fig.  9: (A) Five weeks after transplantation endogenous epididymal fat pads (endo), the 
portal-drained transplant (pTx) and the caval-drained transplant (cTx) were collected and 
rtPCR was performed. Results are the mean ± SEM of 3-7 animals. ** p < 0.01 pTx vs cTx 
(ANOVA). (B) IL-6 was measured in systemic and portal plasma samples of mice receiving a 
portal-drained fat transplant (pTx) and in sham operated mice. Results are the mean of ± SEM 
of 8-10 animals. (C) Five weeks after transplantation liver tissue was collected and rtPCR was 
performed. Results are the mean ± SEM of 5 animals.  
 
 
To substantiate the potential contribution of IL-6 to the induction of insulin resistance in 
portal transplanted mice, epididymal fat pads of an IL-6 knockout donor were transplanted 
into a wildtype recipient (pTx-IL6KO). As shown in Fig. 10A, glucose tolerance of such 
transplanted mice was not impaired compared to sham-operated wildtype mice. Moreover, the 
insulin-induced increase in Akt-phosphorylation in liver samples was completely maintained 
in these mice (Fig. 10B) in contrast to mice receiving a portal-drained transplant from 
wildtype mice (Fig. 4). These results point towards a causative role for IL-6 in the 
development of insulin resistance in portal transplanted mice.  The mRNA expression levels 
of proinflammatory cytokines were strongly downregulated in portal-transplanted IL-6 
deficient fat pads compared to portal-transplanted fat pads of wildtype mice (Fig. 10C). This 
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suggests a common regulatory effect of IL-6 on other proinflammatory cytokines. 
Additionally, hepatic mRNA expression of SOCS-3 of portal transplanted mice, receiving IL6 
deficient fat pads, was no longer enhanced as it was shown for mice receiving a transplant 
from wildtype mice (Fig. 10D). 
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Fig. 10: Both epididymal fat pads were removed from an IL6-knockout mouse (donor) and 
stitched to the mesenterium of a wildtype mouse (recipient; pTx-IL6KO). (A) Intraperitoneal 
glucose tolerance test (2 g glucose/kg body weight) was performed four weeks after surgical 
procedure in mice receiving portal transplants (pTx-IL6KO; ) or in sham-operated mice (). 
(B) Insulin (1U/kg) was injected i.p. in overnight fasted mice 5 weeks after transplantation. 
Liver and muscle samples were harvested 15 minutes later and phosphorylation of Akt at 
S473 was determined by Western blotting. A representative blot is shown in the upper panel. 
(C) Five weeks after transplantation, portal-transplanted fat pads of wildtype donor (pTx) and 
IL6-KO donor mice (pTxIL6-KO) were collected and rtPCR was performed. Results are the 
mean of ± SEM of 3 animals *p<0.05 (D) Five weeks after transplantation, liver of pTx-
IL6KO mice was collected and rtPCR was performed. Results are the mean of ± SEM of 3 
animals.  
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As shown in Figure 9A, mRNA expression of FasL was significantly higher in portal-
transplanted compared to caval-transplanted fat pads. Such result suggests increased Fas 
activation in portal transplanted fat pad, which may induce secretion of proinflammatory 
cytokines such as IL-6. To estimate whether Fas activation contributes to the declined glucose 
homeostasis, epididymal fat pads of an adipocyte-specific Fas-knockout (AFasKO) mouse 
were transplanted portally to wildtype mice. It was shown by Wueest et al., that mice lacking 
Fas in adipocytes showed less adipose tissue inflammation and were partly protected from 
deterioration in glucose homeostasis induced by high-fat diet. Interestingly, mice receiving a 
Fas-deficient fat transplant showed normal glucose tolerance similar to sham-operated 
littermates (Fig. 11A). As expected and documented in Fig 11B, Fas was decreased in Fas-
deficient fat transplants, but not in endogenous epididymal fat tissue of transplanted and 
sham-operated mice (Fig.11B). 
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Fig. 11: Both epididymal fat pads were removed from a adipocyte-specific Fas-knockout 
mouse (donor; AFasKO) and stitched to the mesenterium of a wildtype mouse (recipient; 
pTx-AFasKO). (A) Intraperitoneal glucose tolerance test (2 g glucose/kg body weight) was 
performed four weeks after surgical procedure in mice receiving portal transplants (pTx-
AFasKO; ) or in sham-operated mice (). (B) Epididymal fat tissue of Sham-operated and 
portal transplanted mice as well as the portal transplant was collected and Fas was determined 
by Western blotting. Results are the mean ± SEM of 2-3 animals. 
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 7.2 Impact of fat tissue transplantation on energy balance 
 
Furthermore, weight of different endogenous fat pads was determined in mice receiving either 
a portal- or a caval-drained transplant. As shown in Fig. 12A “total” adipose tissue weight 
(sum of inguinal, epididymal, mesenteric and perinephric fat pads) was slightly decreased in 
caval-transplanted mice compared to portal-transplanted or sham-operated mice. This 
decrease was due to trend wise lower weights of epididymal, mesenteric and perinephric fat 
pads whereas weight of inguinal fat pads were similar in all three groups (Fig. 12B)    
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Fig. 12: (A) Endogenous fat pad mass was determined in portal, caval transplanted and sham-
operated mice after 4 weeks of transplantation. (B) Total fat pad weight was determined for 
all groups (left panel) and calculated as a difference to sham-operated mice (right panel). 
Results are the mean of ± SEM 5-6 animals. 
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Given the above mentioned differences in fat pad weight between portal-transplanted, caval-
transplanted and sham-operated mice we hypothesized that an artificial increase in fat mass by 
fat transplantation will impact on energy balance and that this effect is dependent on fat 
transplant localization. We therefore analyzed food intake, locomotor activity, energy 
expenditure and respiratory quotient in these mice using metabolic cages.  
Food intake was measured hourly during light and dark phase for 24 hours. In Fig.13 the 
absolute food intake is shown for 24 hours. Food intake in mice is higher during dark phase 
than during light phase as they belong to nocturnal rodents. As depicted in Fig. 13B food 
intake during dark phase was similar in all three groups. However, portal and caval 
transplanted mice had an approximately 50 % higher intake during light phase compared to 
sham-operated mice (Fig. 13B). As a consequence, absolute food intake was slightly higher in 
portal-transplanted mice. 
As depicted in Fig. 13A and Fig. 13B no apparent differences were found in energy 
expenditure and respiratory quotient between the three groups. However, mice receiving a 
portal-drained fat transplant showed an approx. 20% reduction in locomotor activity during 
the light phase (Fig. 14C). 
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Fig. 13: (A) Absolute food intake of sham-operated, portal (pTx) and caval (cTx) transplanted 
mice was measured hourly during 24 h using metabolic cages. (B) Absolute food intake is 
shown in light and dark phase. Results are the mean of ± SEM 5-6 animals. 
 
 
 
 
 
 
 
 
 
 
 43
A 
 
 
 
 
 
 
 
 Sham cTx pTx
0
20
40
60
80
100
120
Light
En
er
gy
 E
xp
en
di
tu
re
 P
er
ce
nt
ile
(k
ca
l/k
g/
hr
)
Sham cTx pTx
0
20
40
60
80
100
120
Dark
En
er
gy
 E
xp
en
di
tu
re
 P
er
ce
nt
ile
(k
ca
l/k
g/
hr
)
 
 
B 
 
 
 
  
 
 
C 
 
  
 
 
 
Light
Sham cTx pTx
0
20
40
60
80
100
120
R
es
pi
ra
to
ry
 q
uo
tie
nt
as
 a
 p
er
ce
nt
ag
e 
of
 s
ha
m
 c
on
tr
ol
Dark
Sham cTx pTx
0
20
40
60
80
100
120
R
es
pi
ra
to
ry
 q
uo
tie
nt
as
 a
 p
er
ce
nt
ag
e 
of
 s
ha
m
 c
on
tr
ol
 
 
C 
 Light Dark 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 14: Energy expenditure (A), respiratory quotient (B) and activity (C) were determined as 
percentile for light and dark phase of a 24 h measurement using metabolic cages. Results are 
the mean of ± SEM 5-6 animals. 
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 In summary, mice receiving a portal-drained fat transplant show increased food intake and 
reduced locomotor activity during light phase, which might be responsible for the observed 
differences in fat mass and might impact on glucose homeostasis. 
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8  Discussion 
 
8.1 The impact of fat tissue localization and its venous drainage on glucose  
      homeostasis 
 
 
The “portal hypothesis” proposes that the liver is directly exposed to free fatty acids and 
cytokines increasingly released from visceral fat tissue into the portal vein of obese subjects 
and, thus, rendering visceral fat accumulation particularly hazardous for the development of 
hepatic insulin resistance and type 2 diabetes (29-30). In this study, fat mass was depot-
specifically, artificially increased utilizing a novel fat transplantation model. In accordance 
with the portal hypothesis, this study demonstrates that fat transplant localization impacts on 
glucose homeostasis through its venous drainage.  
The metabolic relevance of specific fat depots, also their artificial increase by adipose tissue 
transplantation, has been discussed in previous studies (24, 31-33). In this context, the 
localization and especially the drainage of the described adipose tissue is often not clarified. 
Fat pads transplanted into intra-abdominal compartments have been described as visceral fat 
transplants, without making sure, that these pads are effectively drained into portal vein. 
Moreover, the origin and the amount of transplanted tissue vary in previous studies. However, 
in most of these studies epididymal fat pads were used as donor fat, as it was also the case in 
this study.  
Besides fat pad origin, the importance of adipose tissue drainage has to be considered when 
effects on metabolism are determined. In an earlier study (24), glucose tolerance was 
improved in mice receiving a systemic drained transplant. These findings were confirmed by 
a more recent study from Hocking et al. (32). The aim of the present study was to develop a 
portal transplantation model mimicking visceral fat tissue accumulation. In contrast to mice 
receiving a systemically drained fat transplant, glucose tolerance was deteriorated in portal 
transplanted mice. Interestingly, Tran et al. found no changes in glucose tolerance in their 
model of intraabdominal fat pad transplantation. However, in contrast to our study, fat 
transplants in their study were drained both to the caval as well as to the portal vein. 
Similarly, we found here no alterations in glucose tolerance in mice receiving both a caval-
drained as well as a portal-drained fat transplant (Fig. 4B). This is potentially due to the fact 
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that the beneficial metabolic effect of the caval drained fat transplant is balanced by the 
detrimental effect of the portal drained transplant. 
Hepatic insulin resistance in mice receiving portal drained fat transplants corresponds with the 
conclusion of Miyazaki et al. (34) which postulates that visceral fat accumulation as opposed to 
subcutaneous fat accumulation is associated with hepatic insulin resistance. Interestingly, 
hepatic insulin resistance found in our study was not associated with hepatic steatosis or 
increased Kupffer cell activation (Fig. 8) as it was observed in high fat diet-induced hepatic 
insulin resistance (28, 35). These changes might be due to a direct effect of high fat diet on 
liver metabolism or due to an increased release of FFAs from visceral adipose tissue in high 
fat diet-fed mice. Accordingly, FFAs levels were not increased in mice receiving portal 
drained transplants.  
Hepatic insulin resistance is often discussed in association with adipose tissue inflammation 
suggesting that activated macrophages produce pro-inflammatory cytokines such as IL-6 (15, 
19-20). Moreover, chronic exposure to IL-6 inhibits hepatic insulin receptor signalling (18) 
and IL-6 activates the negative insulin signalling regulator SOCS-3 in C57BL/6J mice (20) 
implicating IL-6 as a contributor to the development of insulin resistance in obesity, 
particularly in the liver. Correspondingly, IL-6 expression in portal transplanted adipose tissue 
and IL-6 levels in the portal vein of mice receiving portal drained transplants were increased 
(Fig. 9A, B). Moreover, hepatic SOCS-3 expression was induced (Fig. 9C) and, consistently, 
insulin-stimulated Akt phosphorylation was reduced in the liver of these mice. This 
impairment of hepatic insulin signalling was not observed in mice receiving IL-6 deficient fat 
transplants (Fig. 9B). Hepatic SOCS-3 expression was accordingly not induced in those mice 
(Fig. 9D). Thus, these results point towards a causative role for IL-6 in the development of 
insulin resistance in portal transplanted mice.  
Expression of pro-inflammatory cytokines, including IL-6, was increased in caval as well as 
portal transplanted fat pads (Fig. 9C). Remarkably, glucose metabolism was only deteriorated 
when transplants were drained to the portal vein. Moreover, portal transplantation of 
peritoneal tissue that did not contain adipose tissue had no effect on glucose tolerance (Fig. 
4B). These data suggest that the transplantation procedure on its own does not deteriorate 
glucose homeostasis, for example, by altering the delivery of inflammatory mediators from 
the gastro-intestinal tract. Such finding emphasizes the importance of fat tissue localization 
and, thus, vascular drainage and indicates that the increased production of pro-inflammatory 
cytokines as it is found in obesity is particularly detrimental when released into the portal 
circulation supporting the portal hypothesis (30). Furthermore, besides IL-6 other factors may 
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have contributed to the deterioration of glucose tolerance and hepatic insulin resistance. 
Interestingly, lack of IL-6 also reduced expression of IL-1β in adipose tissue (Fig. 10C). 
Rotter et al. suggested that IL-6 induce insulin resistance in concert with other cytokines that 
are also upregulated in adipocytes (36). Especially IL-6 and IL-1β were shown to mediate the 
change of hepatic glucose metabolism, influencing the glucoregulatory action of insulin 
through their signal pathways involving protein phosphorylation (13, 37).  
Interestingly, we found increased levels of FasL in portal transplanted fat pads. We previously 
reported that Fas activation by FasL-treatment induced secretion of IL-6 in 3T3-L1 
adipocytes.(38). Conversely, adipocyte-specific Fas-knockout mice showed decreased IL-6 
expression in adipose tissue and reduced circulating IL-6 levels (25). Thus, FasL-induced Fas-
activation might be responsible for increased IL-6 secretion of portal transplanted fat pads 
ultimately inducing hepatic insulin resistance. Indeed, FasL expression was not reduced in 
portal transplanted IL-6 deficient fat pads suggesting that Fas-activation may be indeed 
upstream of IL-6 release (Fig. 10C). Furthermore, mice receiving fat transplants from 
AFasKO mice showed normal glucose tolerance. (Fig. 11A). Therefore, our results may 
suggest that Fas-activation may an important early step in the induction of pro-inflammatory 
cytokines in adipose tissue, e.g. in obesity.  
 
 
8.2 Impact of fat tissue transplantation on energy balance 
 
As depicted in Fig. 12B, endogenous mass of different fat pads was decreased in mice 
receiving a caval drained transplant whereas those pads of mice with portal drained 
transplants maintained almost the same fat mass as sham-operated mice. This suggests a self-
regulatory process to maintain adipose tissue mass in caval transplanted but not in portal 
transplanted mice. We hypothesized that caval transplanted fat pads may secret a humoral 
factor that inhibits food intake and/or increases energy expenditure whereas portal 
transplanted fat pads do not secret such factor or the latter is removed during liver passage 
before reaching the brain. Thus, in collaboration with Prof. Thomas Lutz’s group food intake 
and energy expenditure was analyzed. 
Indeed, energy balance was affected by transplantation of additional adipose tissue. 
Particularly, mice with portal drained fat transplants had a slightly higher food intake than 
caval transplanted or sham-operated mice (Fig. 13A). Moreover, physical activity was 
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reduced only in mice receiving a portal transplant (Fig. 14C). Interestingly, several brain 
regions have been associated with energy homeostasis. At the molecular level, the 
melanocortin system plays a major role. Stimulation of proopiomelanocortin (POMC) neurons 
results finally in decreased food intake and increased energy expenditure (39-40). Leptin was 
previously shown to stimulate POMC neurons and hence, a reduction in circulating leptin 
levels lead to decreased stimulation of the POMC neurons resulting in higher food intake and 
decreased energy expenditure. So far, we have not found any differences in circulating leptin 
levels. However, leptin sensitivity may be different. Thus, we plan to analyze leptin signaling 
in the hypothalamus.  
Mice are nocturnal animals, i.e. food intake is much higher during dark phase. Interestingly, 
increased food intake in mice receiving a fat transplant was due to increased food intake 
during light phase. In contrast, food intake during dark phase was not different from sham-
operated or caval transplanted mice (Fig. 13B). As expected, sham-operated mice showed a 
normal food intake profile. Such finding may suggest alterations in circadian clock regulation. 
It has been suggested that changes in the metabolic state associated with obesity affect 
circadian rhythms with regard to activity, feeding and the cycling of clock genes and their 
downstream clock-controlled targets (41). Thus, our findings indicate that changes 
implemented by adipose tissue transplantation may alter the circadian clock depending on 
transplant localization. Ongoing projects in our laboratory will further evaluate the potential 
role of altered regulation in clock genes. 
 
Using a novel adipose tissue transplantation paradigm we demonstrate that portal delivery of 
cytokines such as IL-6 induces hepatic insulin resistance and impacts on energy homeostasis. 
Thus, we provide further evidence for the "portal hypothesis", which explains the strong 
association between visceral fat accumulation and (hepatic) insulin resistance by increased 
drainage of pro-inflammatory cytokines and lipids to the portal vein.     
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